A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Trial Profile

A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Brilacidin (Primary) ; Daptomycin
  • Indications Abscess; Methicillin-resistant Staphylococcus aureus infections; Post-traumatic infections; Postoperative infections; Skin and soft tissue infections; Staphylococcal infections; Streptococcal infections; Wound infections
  • Focus Therapeutic Use
  • Sponsors Cellceutix
  • Most Recent Events

    • 30 Oct 2015 According to Cellceutix media release, company had a positive end-of-phase 2 meeting with the FDA in July 2015.
    • 30 Oct 2015 Results published in Cellceutix media release.
    • 21 Sep 2015 Results assessing population pharmacokinetics presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top